FY2024 EPS Estimates for BriaCell Therapeutics Corp. Increased by HC Wainwright (TSE:BCT)

BriaCell Therapeutics Corp. (TSE:BCT) – Equities researchers at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of BriaCell Therapeutics in a research report issued to clients and investors on Thursday, September 19th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($1.09) per share for the year, up from their prior forecast of ($1.90). HC Wainwright also issued estimates for BriaCell Therapeutics’ Q4 2024 earnings at ($0.71) EPS, FY2025 earnings at ($0.35) EPS, FY2026 earnings at ($0.33) EPS, FY2027 earnings at ($0.26) EPS and FY2028 earnings at ($0.16) EPS.

BriaCell Therapeutics Price Performance

BCT opened at C$0.87 on Monday. BriaCell Therapeutics has a one year low of C$0.64 and a one year high of C$8.65. The firm has a market capitalization of C$26.72 million, a price-to-earnings ratio of -1.74 and a beta of 1.74. The business has a 50 day simple moving average of C$0.93 and a two-hundred day simple moving average of C$2.00.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.